Nuvalent, Inc. 8-K

What Happened

• Nuvalent, Inc. announced on April 7, 2026 (via Form 8-K, Item 8.01) that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for neladalkib. The submission is for the treatment of tyrosine kinase inhibitor‑pretreated advanced ALK‑positive non‑small cell lung cancer (ALK+ NSCLC).
• The 8‑K was signed by Deborah A. Miller, Ph.D., Chief Legal Officer and Secretary.

Key Details

• Filing type: Form 8‑K (Item 8.01 — Other Events) filed April 7, 2026.
• Regulatory action: NDA submitted to the U.S. FDA for neladalkib.
• Indication: Tyrosine kinase inhibitor‑pretreated advanced ALK‑positive non‑small cell lung cancer.
• Company contact/signature: Deborah A. Miller, Ph.D., Chief Legal Officer and Secretary.

Why It Matters

• Submitting an NDA is a formal regulatory milestone: it starts the FDA review process that could lead to approval and potential commercialization if the FDA finds the application acceptable.
• For investors, the announcement signals progress on Nuvalent’s lead clinical program (neladalkib) and represents a key step toward potential future revenue, but the filing does not disclose review timelines, trial results, or financial projections.